Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
Guardant HealthGuardant Health(US:GH) Businesswire·2026-03-30 20:05

公司动态 - Guardant Health Inc 是一家领先的精准肿瘤学公司 [1] - 公司宣布其Guardant InfinityAI生成的真实世界证据促成了ENHERTU®在日本的近期获批 [1] - ENHERTU®由第一三共株式会社开发并商业化 [1] 产品与市场 - ENHERTU®获批用于治疗HER2阳性晚期或复发性实体癌患者 [1] - HER2阳性定义为HER2基因扩增或免疫组化检测3+ [1] - 适用患者群体为对标准治疗耐药或难治的患者 [1]

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan - Reportify